Early is good announces collaboration with mayo clinic to develop a comprehensive liquid biopsy test for men with advanced prostate cancer

Indianapolis--(business wire)--early is good (eig), a diagnostic company pioneering multi-omic technology, is pleased to announce a collaboration with mayo clinic to develop a comprehensive liquid biopsy for men with advanced prostate cancer. "each year, around 50,000 prostate cancer patients in the us are diagnosed with mcrpc1. currently, treatment strategies are limited to a single omic type leading to avoidable treatment failures and deaths. this collaboration to develop a comprehensive mult.
EIG Ratings Summary
EIG Quant Ranking